CFRX News and Press, ContraFect Corporation

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

ContraFect Corporation (CFRX) is expected to report $-0.66 for Q3 2023

2023-10-30 18:07:12 ET More on Contrafect Seeking Alpha’s Quant Rating on Contrafect Historical earnings data for Contrafect Financial information for Contrafect For further details see: ContraFect files for stock and warrants offering to raise $15M

2023-10-16 09:51:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rite Aid (NYSE: RAD ) stock is on the move Monday after the pharmacy chain filed for Chapter 11 bankruptcy protection in New Jersey. The bankruptcy filing from the compa...

2023-10-16 09:22:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nxu (NASDAQ: NXU ) stock is falling on Monday after the battery cells company reported insider selling of its shares. A filing with the Securities and Exchange Commission (S...

2023-10-16 08:42:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sigma Additive Solutions (NASDAQ: SASI ) stock is falling on Friday as the software company’s shares gave up some gains it received on Friday! Sigma Additive Solution...

2023-10-16 08:19:55 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ContraFect (NASDAQ: CFRX ) stock is rising higher on Monday as investors react to an update from the Food and Drug Administration (FDA). The FDA has informed ContraFect ...

YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Adm...

YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., t...

YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investiga...